Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trialResearch in context

• मुख्य लेखकों: Fuxiang Wang (लेखक), Wen Xiao (लेखक), Yimin Tang (लेखक), Mengli Cao (लेखक), Dan Shu (लेखक), Tetsuya Asakawa (लेखक), Yechun Xu (लेखक), Xiangrui Jiang (लेखक), Leike Zhang (लेखक), Wei Wang (लेखक), Jianxing Tang (लेखक), Yuansheng Huang (लेखक), Yang Yang (लेखक), Yumei Yang (लेखक), Renhong Tang (लेखक), Jingshan Shen (लेखक), Hongzhou Lu (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Elsevier, 2023-09-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Summary: Background: SIM0417 (SSD8432) is an orally administered coronavirus main proteinase (3CLpro) inhibitor with potential anti-SARS-CoV-2 activity. This study aimed to evaluate the efficacy and safety of SIM0417 plus ritonavir (a pharmacokinetic enhancer) in adults with COVID-19. Methods: This...